N-of-1 drugs push biopharma frontiers

Bespoke drug development could have regulatory, toxicology and accessibility implications for the entire biopharma sector.

Search for this author in:

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Nature Reviews Drug Discovery 19, 151-153 (2020)

doi: 10.1038/d41573-020-00027-x

Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.